ArticleThe journal of behavioral health services & research2026
Health Information Technology Infrastructure and Availability of Medications for Opioid Use Disorder and Naloxone in U.S. Substance Use Disorder Treatment Facilities.
Article in The journal of behavioral health services & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medications for opioid use disorder (MOUD) reduce overdose mortality, yet most individuals with opioid use disorder receive no pharmacotherapy. Facility-level health information technology may reflect broader organizational capacity, but it has rarely been examined as a marker associated with readiness to offer evidence-based opioid care. This cross-sectional secondary analysis of the 2024 National Substance Use and Mental Health Services Survey (N-SUMHSS) Public Use File included a base sample of 20,813 substance use disorder treatment facilities and used complete-case adjusted logistic regression to examine whether exclusive electronic health record (EHR) use, defined as reliance on an EHR with no paper charts, was associated with the availability of buprenorphine, naltrexone, take-home naloxone with overdose education, and co-occurring opioid use disorder services. Models adjusted for ownership, program focus, opioid treatment program (OTP) registration, and financial access characteristics; federally regulated OTP methadone availability served as a regulatory contrast. Among facilities with valid EHR responses (n = 16,107), 68.3% reported exclusive EHR use. Exclusive EHR use was associated with higher adjusted odds of buprenorphine (aOR = 3.05), naltrexone (aOR = 2.90), take-home naloxone with overdose education (aOR = 3.18), and co-occurring services (aOR = 2.33), and more weakly with federally regulated OTP methadone availability (aOR = 1.23). Exclusive EHR use is an organizational marker associated with service availability, but the cross-sectional design and potential residual confounding preclude causal conclusions about whether EHR investment would expand opioid treatment access.
Identifiers
42864480What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.